Categories: News

IMC Says There is Still Time for Federal Government to Put Canadian Patients First by Delaying January 1, 2021 Implementation of PMPRB’s Regulations and Guidelines

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

OTTAWA, ON / ACCESSWIRE / December 29, 2020 / Innovative Medicines Canada (IMC) issued the following statement today regarding the looming implementation of the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines on January 1, 2021.

“While COVID-19 vaccines from several innovative pharmaceutical companies have provided Canadians a glimmer of hope, the pandemic is far from over. Throughout, we have seen just how important the life sciences sector is to Canadians’ health and well-being. Unfortunately, if the federal government proceeds with the implementation, on January 01, 2021, of the amended PMPRB Regulations and Guidelines, Canadians’ access to potentially life-saving new medicines and vaccines will be limited.

“In fact, we are already seeing the negative impact of the changes, even before they come into force. New drugs are not being launched in Canada, clinical trials have declined, and investments in our vital life sciences sector are being scaled back. While January 1 is just days away, there is still time for the federal government to act.

“At a minimum, the Federal Government must delay the implementation of PMPRB’s final regulations and Guidelines until after the pandemic has passed, which will allow all of us to focus on the real priority, which is fighting COVID-19. In addition, a delay will provide the time necessary for industry, patients, and governments at all levels to work together and consider a better path forward.

“To that end, industry has proposed an alternate path to the federal government; one that would allow it to achieve its public policy objectives, without undermining patient access to potentially life-saving medicines, clinical trials in Canada, or investment in the country’s life sciences sector.”

Learn more about Innovative Medicines Canada’s Alternate Proposal.

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development, and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

For further information:
Sarah Dion-Marquis
Media Relations
Telephone: (613) 769-6510
E-mail: sdmarquis@imc-mnc.ca

SOURCE: Innovative Medicines Canada / Médicaments novateurs Canada

View source version on accesswire.com:
https://www.accesswire.com/621642/IMC-Says-There-is-Still-Time-for-Federal-Government-to-Put-Canadian-Patients-First-by-Delaying-January-1-2021-Implementation-of-PMPRBs-Regulations-and-Guidelines

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago